公开(公告)号：EP1377671A2

公开(公告)日：2004-01-07

申请号：EP02714960.8

申请日：2002-02-22

申请人： Novartis AG

发明人： ENNIST, David, Leonard ,  FORRY-SCHAUDIES, Suzanne ,  GORZIGLIA, Mario ,  HALLEN-BECK, Paul, L. ,  HAY, Carl, M. ,  JAKUBCZAK, John, Leonard ,  KALEKO, Michael ,  RYAN, Patricia, Clara ,  STEWART, David, A. ,  XIE, Yuefeng ,  CONNELLY, Sheila ,  POLICE, Seshidhar Reddy ,  CLARKE, Lori ,  PHIPPS, Sandrina ,  CHENG, Cheng

IPC分类号： C12N15/861

CPC分类号： C12N15/86 ,  C12N2710/10343 ,  C12N2800/30 ,  C12N2830/007 ,  C12N2830/008 ,  C12N2830/85 ,  C12N2840/203

摘要： The present invention relates to oncolytic adenoviral vectors and their use in methods of gene therapy. Provided is a recombinant viral vector comprising an adenoviral nucleic acid backbone, wherein said nucleic acid backbone comprises in sequential order : A left ITR, a termination signal sequence, an E2F responsive promoter which is operably linked to a gene essential for replication of the recombinant viral vector, an adenoviral packaging signal, and a right ITR.

公开(公告)号：EP1032696A1

公开(公告)日：2000-09-06

申请号：EP98962352.5

申请日：1998-11-17

申请人： Novartis AG ,  Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.

发明人： CHANG, Yung-Nien ,  HALLENBECK, Paul, L. ,  HAY, Carl, M. ,  STEWART, David, A.

IPC分类号： C12N15/86 ,  C12N7/01 ,  C12N5/10

CPC分类号： C12N15/86 ,  A61K48/00 ,  C12N2710/10343 ,  C12N2830/008 ,  C12N2830/15 ,  C12N2830/30 ,  C12N2830/32 ,  C12N2830/85 ,  C12N2840/20 ,  C12N2840/44

摘要： The invention generally relates to cell-specific expression vectors. It particularly relates to targeted gene therapy using recombinant expression vectors and particularly adenovirus vectors. The invention specifically relates to replication-conditional expression vectors and methods for using them. Such vectors are able to selectively replicate in a target cell or tissue to provide a therapeutic benefit in a tissue from the presence of the vector per se or from one or more heterologous gene products expressed from the vector and distributed throughout the tissue.

公开(公告)号：EP1364038A2

公开(公告)日：2003-11-26

申请号：EP01962700.9

申请日：2001-06-01

申请人： Novartis AG ,  Novartis Pharma GmbH

发明人： JAKUBCZAK, John, Leonard ,  ROLLENCE, Michele, Lynette ,  STEWART, David, A. ,  STEVENSON, Susan, C. ,  HALLENBECK, Paul, L. ,  IDAMKANTI, Neeaja ,  KALEKO, Michael ,  SMITH, Theodore

IPC分类号： C12N15/86 ,  C12N15/34 ,  C12N5/10 ,  C07K14/075 ,  C12N7/04

CPC分类号： C12N7/00 ,  A61K48/00 ,  C07K14/005 ,  C12N15/86 ,  C12N2710/10222 ,  C12N2710/10243 ,  C12N2800/30 ,  C12N2810/405 ,  C12N2810/6018

摘要： This invention relates to mutated adenoviral fiber proteins and adenovirus particles containing such proteins. It further relates to polynucleotides encoding the proteins and vectors containing polynucleotides. It also relates to methods for making and using the adenoviral particles. With the mutated fiber proteins, the adenovirus particles no longer bind to their natural cellular receptor. They can then be 'retargeted' to a specific cell type through the addition of a ligand to the virus capsid, which causes the virus to bind to and infect such cell. Specific fiber mutations are listed, which ablate binding to the natural receptor. Adenovirus particles with certain fiber mutations were found to enhance gene transfer to and expression in liver as compared to viral particles with wild-type fiber.